scholarly journals EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy

2011 ◽  
Author(s):  
Dianjie Lin
Keyword(s):  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Malignant Pleural Effusion ◽  
Favorable Outcome ◽  
Egfr Mutations

scholarly journals Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”

2021 ◽  
pp. 1616-1620
Author(s):  
Umberto Caterino ◽  
Cristiano Cesaro ◽  
Enzo Zamparelli ◽  
Flavio Cesaro ◽  
Alba Palma ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Malignant Pleural Effusion ◽  
Young Patients ◽  
Stage Iv ◽  
Complete Response ◽  
Egfr Mutations ◽  
Therapeutic Success ◽  
Anaplastic Lymphoma ◽  
Stage Iv Disease

Malignant pleural effusion represents a prognostic negative factor on survival conferring stage IV disease. The median of survival is 5 months and a 5-year survival of about 3%. We describe the therapeutic success obtained from different strategies in anaplastic lymphoma kinase (ALK) inhibitors in 2 young women showing malignant pleural effusion secondary to advanced ALK-rearranged lung adenocarcinoma. This report shows that for patients with EGFR mutations in advanced lung adenocarcinoma-associated malignant pleural effusion, complete response to EGFR TKI inhibitor can be observed mostly if pleural effusion and primary lung adenocarcinoma show the same EGFR mutation status.

scholarly journals Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion

Oncogene ◽  
2006 ◽  
Vol 25 (31) ◽  
pp. 4300-4309 ◽  
Author(s):  
H-H Yeh ◽  
W-W Lai ◽  
H H W Chen ◽  
H-S Liu ◽  
W-C Su
Keyword(s):  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Malignant Pleural Effusion

scholarly journals A Case of Lung Adenocarcinoma with Wild-Type EGFR Malignant Pleural Effusion Well Controlled by Treatment with Gefitinib

2012 ◽  
Vol 23 ◽  
pp. xi146
Author(s):  
Y. Ueda ◽  
T. Takahama ◽  
K. Sakai ◽  
H. Miyawaki ◽  
T. Yoshikawa ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Malignant Pleural Effusion ◽  
Wild Type

scholarly journals The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer

2020 ◽  
Author(s):  
Ming-Fang Wu ◽  
Chih-An Lin ◽  
Tzu-Hang Yuan ◽  
Hsiang-Yuan Yeh ◽  
Sheng-Fang Su ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pleural Effusion ◽  
Lung Adenocarcinoma ◽  
Cancer Patients ◽  
Patient Outcomes ◽  
Malignant Pleural Effusion ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Anti Cancer ◽  
Cancer Activity

Abstract Background Malignant pleural effusion (MPE)-macrophage (Mφ) of lung cancer patients within unique M1/M2 spectrum showed plasticity in M1–M2 transition. The M1/M2 features of MPE-Mφ and their significance to patient outcomes need to be clarified; furthermore, whether M1-repolarization could benefit treatment remains unclear. Methods Total 147 stage-IV lung adenocarcinoma patients undergoing MPE drainage were enrolled for profiling and validation of their M1/M2 spectrum. In addition, the MPE-Mφ signature on overall patient survival was analyzed. The impact of the M1-polarization strategy of patient-derived MPE-Mφ on anti-cancer activity was examined. Results We found that MPE-Mφ expressed both traditional M1 (HLA-DRA) and M2 (CD163) markers and showed a wide range of M1/M2 spectrum. Most of the MPE-Mφ displayed diverse PD-L1 expression patterns, while the low PD-L1 expression group was correlated with higher levels of IL-10. Among these markers, we identified a novel two-gene MPE-Mφ signature, IL-1β and TGF-β1, representing the M1/M2 tendency, which showed a strong predictive power in patient outcomes in our MPE-Mφ patient cohort (N = 60, p = 0.013) and The Cancer Genome Atlas Lung Adenocarcinoma dataset (N = 478, p < 0.0001). Significantly, β-glucan worked synergistically with IFN-γ to reverse the risk signature by repolarizing the MPE-Mφ toward the M1 pattern, enhancing anti-cancer activity. Conclusions We identified MPE-Mφ on the M1/M2 spectrum and plasticity and described a two-gene M1/M2 signature that could predict the outcome of late-stage lung cancer patients. In addition, we found that “re-education” of these MPE-Mφ toward anti-cancer M1 macrophages using clinically applicable strategies may overcome tumor immune escape and benefit anti-cancer therapies.

scholarly journals RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer

2011 ◽  
Vol 39 (3) ◽  
pp. 677-684 ◽  
Author(s):  
T.-H. Tsai ◽  
K.-Y. Su ◽  
S.-G. Wu ◽  
Y.-L. Chang ◽  
S.-C. Luo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Pleural Effusion ◽  
Malignant Pleural Effusion ◽  
Egfr Mutations
Sign in / Sign up

Export Citation Format

Share Document